Literature DB >> 17250555

Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus.

P Chuang1, A J Langone.   

Abstract

Aphthous ulceration is a common side effect of sirolimus. These lesions of the oral mucous membranes are often painful and debilitating, leading to either dose reduction or discontinuation of sirolimus in a significant number of patients. We report that the direct application of clobetasol, a high potency topical steroid, led to prompt resolution of the aphthous ulcers that developed in our renal transplant patients on sirolimus-based immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17250555     DOI: 10.1111/j.1600-6143.2006.01678.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  9 in total

Review 1.  Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.

Authors:  Viswanath Reddy Belum; Andrea Cercek; Virginia Sanz-Motilva; Mario E Lacouture
Journal:  Curr Treat Options Oncol       Date:  2013-09

Review 2.  Common toxicities of mammalian target of rapamycin inhibitors.

Authors:  Scott A Soefje; Anand Karnad; Andrew J Brenner
Journal:  Target Oncol       Date:  2011-04-16       Impact factor: 4.493

Review 3.  Urban legends: recurrent aphthous stomatitis.

Authors:  L Baccaglini; R V Lalla; A J Bruce; J C Sartori-Valinotti; M C Latortue; M Carrozzo; R S Rogers
Journal:  Oral Dis       Date:  2011-08-04       Impact factor: 3.511

Review 4.  Next Generation Strategies for Geroprotection via mTORC1 Inhibition.

Authors:  Sabrina N Dumas; Dudley W Lamming
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-01-01       Impact factor: 6.053

5.  Recognition and Management of Oral Mucosal Injury Caused by Mammalian Target of Rapamycin Inhibitors: A Case Series.

Authors:  Timothy F Meiller; Sharon Varlotta; Dianna Weikel
Journal:  Case Rep Oncol       Date:  2015-08-19

6.  Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.

Authors:  Ji Hyun Yu; Kyoung Woon Kim; Bo-Mi Kim; Byung Ha Chung; Mi-La Cho; Bum Soon Choi; Cheol Whee Park; Yong-Soo Kim; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2016-03-11       Impact factor: 2.884

Review 7.  Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.

Authors:  Mark Davies; Anurag Saxena; John C Kingswood
Journal:  Orphanet J Rare Dis       Date:  2017-02-15       Impact factor: 4.123

Review 8.  Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management.

Authors:  Solène Huynh Dagher; Astrid Blom; Hedi Chabanol; Elisa Funck-Brentano
Journal:  Int J Womens Dermatol       Date:  2021-09-28

Review 9.  Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.

Authors:  Douglas E Peterson; Joyce A O'Shaughnessy; Hope S Rugo; Sharon Elad; Mark M Schubert; Chi T Viet; Cynthia Campbell-Baird; Jan Hronek; Virginia Seery; Josephine Divers; John Glaspy; Brian L Schmidt; Timothy F Meiller
Journal:  Cancer Med       Date:  2016-06-23       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.